17 November 2021 - - US-based biotechnology company BioAge Labs, Inc has appointed Dov Goldstein, M.D., M.B.A. as chief financial officer and Ann Neale as chief development officer, the company said.

Both officers are the first to hold their respective positions at BioAge.

Goldstein comes to BioAge with extensive strategic financial experience in the biopharmaceutical sector.

He joins BioAge from Indapta Therapeutics, where he served as chief financial and business officer from 2020 to 2021 and was responsible for the company's growth strategies as well as operational finance and business development.

Previously, he was CEO at RIGImmune from 2018 to 2020, CFO of Schrödinger from 2017 to 2018, and a partner at Aisling Capital from 2006 to 2017.

From 2014 to 2015, he served as the CFO of Loxo Oncology, which was later acquired by Lilly for USD 8bn.

From 2000 to 2005, he served as CFO of Vicuron Pharmaceuticals (acquired by Pfizer in 2005 for USD 1.9bn), where he raised over USD 250m in equity financing and played major roles in the company's partnership transactions.

He currently serves on the board of directors of Gain Therapeutics, Neubase Therapeutics, and Coya Therapeutics, and previously held seats on the boards of ADMA Biologics, Cempra Pharmaceuticals, Durata Therapeutics, Esperion Therapeutics, and Loxo Oncology.

He has an MD from Yale School of Medicine, an MBA from Columbia Business School, and a BS in Biological Sciences from Stanford University.

Neale has over 25 years leadership experience as a biotech executive, leading global multidisciplinary teams to advance molecules through the development pipeline and deliver on strategic objectives.

Most recently, she served as senior vice president Development Operations at Principia Biopharma, where she defined operations and resourcing strategy for multiple global early and late phase clinical programs while scaling development functions.

After Principia was acquired by Sanofi for USD 3.6bn in September 2020, Neale led the transition and integration of global clinical development operations.

Previously, she served as SVP Clinical Operations and Patient Affairs at Science 37 in 2017, VP Clinical Operations and Data Assessment at XOMA from 2014 to 2017, VP Clinical Operations at Biotie Therapies (acquired by Acorda Therapeutics) from 2007 to 2014, and VP Clinical Operations at Saegis Pharmaceuticals (acquired by Lundbeck) from 2004 to 2006. She holds a BS in Nursing from the University of Minnesota.

BioAge is a clinical-stage biotechnology company developing a pipeline of treatments to extend healthy lifespan by targeting the molecular causes of aging.

The company uses its discovery platform, which combines quantitative analysis of proprietary longitudinal human samples with detailed health records tracking individuals over the lifespan, to map out the key molecular pathways that impact healthy human aging, thus revealing the causes of age-related disease.

By targeting the mechanisms of aging with a large and mechanistically diverse portfolio of drugs, BioAge will unlock opportunities to treat or even prevent these diseases in entirely new ways.

To date, BioAge has raised USD 127m from Andreessen Horowitz, Kaiser Foundation Hospitals, and others. BioAge currently has three clinical-stage programs in their growing portfolio.